Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background: Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not mutated, the MEK gene frequently is. Binimetinib is a MEK inhibitor which targets MEK. It is important to determine if this drug can be a good treatment option in those who cannot benefit treatment with BRAF inhibitors. Objective: To see if binimetinib is an effective treatment for hairy cell leukemia th

Trial Details

NCT ID

NCT04322383

Phase

PHASE2

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• binimetinib

Locations (sample)

• Bethesda, Maryland, United States|38.98067,-77.10026

Key Eligibility Criteria

• Histologically confirmed diagnosis of HCL or HCLv according to morphological and immunophenotypic criteria of World Health Organization (WHO) class…
• Absolute neutrophil count (ANC) \<1 x10\^3/mcL
• Hemoglobin \<10g/dL
• Platelets\<100 x10\^3/mcL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →